Search bioRxiv⌕ Search

Biology subjects

Pendergrass, R. K.

Publications and source records attributed to Pendergrass, R. K..

2 recordsLinked to original sources

Systematic assessment of machine learning-based variant annotation methods for rare variant association testing

Machine learning-based annotation methods are increasingly used to assess the pathogenicity of genetic variants, but their performance at prioritizing variants for gene-level association testing remains poorly characterized. Here, we systematically benchmark five annotation methods -- CADD v1.6, CADD v1.7, AlphaMissense, ESM-1b, and GPN-MSA -- using four primary gene-based tests and six annotation-level aggregation tests across 14 quantitative traits measured in up to 350,377 UK Biobank participants. Using a novel framework based on Wasserstein dis-tances, we quantify how annotation choice affects test calibration and power. Tests using CADD annotations achieve the highest signal separation, while tests using AlphaMissense annotations exhibit systematically lower calibration. All combinations of methods produced significant re-sults that were enriched (1.8-5.8-fold) for loss-of-function intolerant genes, though tests using GPN-MSA annotations displayed the highest such enrichment. Replication across symmetric phenotypes and loss-of-function burden tests was generally similar across methods. Our anal-ysis provides practical guidance for annotation method selection in rare variant studies and establishes a distributional framework for calibration assessment.

bioinformatics↗

Genetic regulation of the human plasma proteome in 54,306 UK Biobank participants

The UK Biobank Pharma Proteomics Project (UKB-PPP) is a collaboration between the UK Biobank (UKB) and thirteen biopharmaceutical companies characterising the plasma proteomic profiles of 54,306 UKB participants. Here, we describe results from the first phase of UKB-PPP, including protein quantitative trait loci (pQTL) mapping of 1,463 proteins that identifies 10,248 primary genetic associations, of which 85% are newly discovered. We also identify independent secondary associations in 92% of cis and 29% of trans loci, expanding the catalogue of genetic instruments for downstream analyses. The study provides an updated characterisation of the genetic architecture of the plasma proteome, leveraging population-scale proteomics to provide novel, extensive insights into trans pQTLs across multiple biological domains. We highlight genetic influences on ligand-receptor interactions and pathway perturbations across a diverse collection of cytokines and complement proteins, and illustrate long-range epistatic effects of ABO blood group and FUT2 secretor status on proteins with gastrointestinal tissue-enriched expression. We demonstrate the utility of these data for drug target discovery by extending the genetic proxied effect of PCSK9 levels on lipid concentrations, cardio- and cerebro-vascular diseases, and additionally disentangle specific genes and proteins perturbed at COVID-19 susceptibility loci. This public-private partnership provides the scientific community with an open-access proteomics resource of unprecedented breadth and depth to help elucidate biological mechanisms underlying genetic discoveries and accelerate the development of novel biomarkers and therapeutics.

genetics↗